*DJ Elbit Imaging Announces Signing of an Agreement for the Sale of Up to 50% of the Shr Cap of Elbit Medical LTD.
*DJ Elbit Imaging Announces Signing of an Agreement for the Sale of Up to 50% of the Shr Cap of Elbit Medical LTD.
Press Release: ELBIT IMAGING ANNOUNCES THE SIGNING OF AN AGREEMENT FOR THE SALE OF UP TO 50% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.
新聞稿：埃爾比特影像宣佈簽署出售埃爾比特醫療有限公司至多50%股本的協議
ELBIT IMAGING ANNOUNCES THE SIGNING OF AN AGREEMENT FOR THE SALE OF UP TO 50% OF THE SHARE CAPITAL OF ELBIT MEDICAL LTD.
埃爾比特影像公司宣佈簽署一項協議，出售埃爾比特醫療有限公司最多50%的股本。
Tel Aviv, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated July 18, 2018, that it has signed a Share Purchase Agreement ("SPA") with an SPV related to Exigent Capital Group ("SPV") for the sale of between 11,574,146 ordinary shares of Elbit Medical Technologies Ltd. ("Elbit Medical") (5% of its outstanding share capital) and 115,741,467 ordinary shares of Elbit Medical (50% of its outstanding share capital) (the "Maximum Quantity") for a price per share of NIS 0.96 ($0.26 based on the NIS-US$ representative rate of exchange as of today) ("Per Share Price").
以色列特拉維夫，2018年8月8日(環球通訊社)-埃爾比特成像有限公司(TASE，NASDAQ：EMITF)(以下簡稱埃爾比特或該公司)今天宣佈，繼2018年7月18日的新聞稿之後，已與一家與Exigent Capital Group(“SPV”)相關的SPV簽署購股協議，出售Elbit Medical Technologies Ltd.(“Elbit Medical”)的11,574,146股普通股(佔其已發行股本的5%)和Elbit Medical的115,741,467股普通股(佔其已發行股本的50%)(“最高數量”)，每股價格為0.96新謝克爾(按新謝克爾-美元代表價格計算為0.26美元)。
Under the terms of the SPA, the SPV is to purchase 11,574,146 shares of Elbit Medical on or before August 27, 2018, which date may be deferred by up to seven (7) days upon the SPV's prior written request (the: "Initial Closing").
根據SPA的條款，SPV將在2018年8月27日或之前購買Elbit Medical的11,574,146股票，如果SPV事先提出書面請求，該日期可能會推遲至多七(7)天(以下簡稱“初步成交”)。
During the period from the Initial Closing until November 26, 2018, the SPV may purchase additional shares up to the Maximum Quantity (including the shares purchased at the Initial Closing), at the Per Share Price, but it is not obligated to do so.
自初始成交至2018年11月26日期間，SPV可以按每股價格增持不超過最大數量的股份(包括初始成交時購買的股份)，但沒有義務這樣做。
If, prior to November 26, 2018, the Company receives a binding, irrevocable offer from a third party to acquire Elbit Medical shares for a price per share (the "Offer Price") at least 7.5% higher than the Per Share Price, then the SPV shall have the right of first refusal ("Right of First Refusal").
如果在2018年11月26日之前，本公司收到第三方提出的具有約束力的、不可撤銷的要約，以每股價格(“要約價”)至少比每股價格高出7.5%的價格收購Elbit Medical股票，則SPV擁有優先購買權(“優先購買權”)。
In addition, in such event, the SPV shall have the right to tag-along with such sale of shares to the offeror. In the event that the SPV does not exercise its Right of First Refusal, the SPV shall be entitled to compensation as specified in the SPA.
此外，在這種情況下，SPV有權在向要約人出售股份的同時貼上標籤。如果SPV沒有行使優先購買權，SPV有權獲得SPA規定的賠償。
The parties also entered into a three-year voting agreement (that will become effective only if and to the extent that the SPV will purchase from the Company shares of Elbit Medical that constitutes at least 10% of Elbit Medical's outstanding share capital) regarding the appointment of directors in the Company.
雙方還就公司董事的任命簽訂了一份為期三年的投票協議(只有當SPV從本公司購買Elbit Medical的股份，該股份至少佔Elbit Medical已發行股本的10%時，該協議才會生效)。
During the term of the voting agreement, each party shall have a right of first offer with respect to any sale of shares by the other party, subject to certain exceptions.
在投票協議期限內，除某些例外情況外，每一方對另一方的任何股份出售都有第一要約的權利。
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects, " "anticipates," "projects," "predicts," "estimates," "aims," "believes, " "hopes," "potential" or similar words and includes relating to the possibility of completing the transaction with the SPV. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those projected, expressed or implied in the forward-looking statements. Such risks and uncertainties include, without limitation, the risk that the SPV will be unable to complete the transaction and purchase Elbit Medical shares. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 27, 2018. Any forward-looking statements contained in this press release speaks only as of the date of this press release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in this press release will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
本新聞稿包含1995年“私人證券訴訟改革法”所指的“前瞻性陳述”。此類聲明的前綴可以是“打算”、“可能”、“將會”、“計劃”、“預期”、“預期”、“項目”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語，包括與完成與SPV的交易的可能性有關的詞語。前瞻性陳述基於某些假設，會受到各種已知和未知的風險和不確定因素的影響，其中許多風險和不確定因素是公司無法控制的，無法預測或量化，因此，實際結果可能與前瞻性陳述中預測、表達或暗示的結果大不相同。此類風險和不確定性包括但不限於SPV無法完成交易和購買Elbit Medical股票的風險。有關公司的更詳細信息以及可能影響前瞻性陳述實現的風險因素，請參閲公司提交給美國證券交易委員會(SEC)的文件，包括公司於2018年4月27日提交給證券交易委員會的Form 20-F年度報告。本新聞稿中包含的任何前瞻性陳述僅代表截至本新聞稿發佈之日的情況，我們告誡現有投資者和潛在投資者不要過度依賴此類陳述。此類前瞻性陳述並不聲稱是對未來事件或情況的預測，因此，不能保證本新聞稿中包含的任何前瞻性陳述都將被證明是準確的。我們沒有義務更新或修改任何前瞻性陳述。
About Elbit Imaging Ltd.
關於埃爾比特成像有限公司
Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) land in India which is designated for sale (and which was initially designated for residential projects); and (iii) land in Eastern Europe which is designated for sale (and which was initially designated for development of commercial centers).
埃爾比特成像有限公司經營以下主要業務領域：(I)通過我們在InSightec Ltd.和Gamida Cell Ltd.的間接持股經營醫療行業；(Ii)指定出售的印度土地(最初指定用於住宅項目)；以及(Iii)東歐指定出售的土地(最初指定用於商業中心開發)。
For Further Information:
Company Contact
Ron Hadassi
CEO and Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
欲瞭解更多信息，請訪問：公司聯繫人羅恩·哈達西首席執行官兼董事會主席電話：+972-3-608-6048傳真：+972-3-608-6050郵箱：ron@elbitimaging.com
(END) Dow Jones Newswires
(完)道瓊通訊社
August 08, 2018 07:19 ET (11:19 GMT)
2018年8月8日東部時間07：19(格林尼治標準時間11：19)
*DJ Elbit Imaging Announces Signing of an Agreement for the Sale of Up to 50% of the Shr Cap of Elbit Medical LTD.
*DJ埃爾比特成像公司宣佈簽署一項協議，出售埃爾比特醫療有限公司Shr Cap最多50%的股份。
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
(更多信息)道瓊斯通訊社(212-416-2800)
August 08, 2018 07:48 ET (11:48 GMT)
2018年8月8日東部時間07：48(格林尼治標準時間11：48)
Copyright (c) 2018 Dow Jones & Company, Inc.
版權所有(C)2018年道瓊斯公司
譯文內容由第三人軟體翻譯。